![Marie-Paul Lachaud](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marie-Paul Lachaud
Keine laufenden Positionen mehr
Karriereverlauf von Marie-Paul Lachaud
Ehemalige bekannte Positionen von Marie-Paul Lachaud
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARATANA THERAPEUTICS INC | Corporate Officer/Principal | 26.03.2013 | - |
Ausbildung von Marie-Paul Lachaud
École Nationale Vétérinaire d'Alfort | Undergraduate Degree |
Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Statistik
International
Frankreich | 3 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sektoral
Consumer Services | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Aratana Therapeutics, Inc.
![]() Aratana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS. | Health Technology |
- Börse
- Insiders
- Marie-Paul Lachaud
- Erfahrung